Toll Free: 1-888-928-9744

Eukaryotic Translation Initiation Factor 4E (eIF-4E) - Pipeline Review, H1 2016

Published: May 31, 2016 | Pages: 38 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Eukaryotic Translation Initiation Factor 4E (eIF-4E) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Eukaryotic Translation Initiation Factor 4E (eIF-4E) - Pipeline Review, H1 2016', provides in depth analysis on Eukaryotic Translation Initiation Factor 4E (eIF-4E) targeted pipeline therapeutics. 

The report provides comprehensive information on the Eukaryotic Translation Initiation Factor 4E (eIF-4E), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Eukaryotic Translation Initiation Factor 4E (eIF-4E) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Eukaryotic Translation Initiation Factor 4E (eIF-4E)
- The report reviews Eukaryotic Translation Initiation Factor 4E (eIF-4E) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Eukaryotic Translation Initiation Factor 4E (eIF-4E) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Eukaryotic Translation Initiation Factor 4E (eIF-4E) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Eukaryotic Translation Initiation Factor 4E (eIF-4E) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Eukaryotic Translation Initiation Factor 4E (eIF-4E)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Eukaryotic Translation Initiation Factor 4E (eIF-4E) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Eukaryotic Translation Initiation Factor 4E (eIF-4E) Overview 6 Therapeutics Development 7 Eukaryotic Translation Initiation Factor 4E (eIF-4E) - Products under Development by Stage of Development 7 Eukaryotic Translation Initiation Factor 4E (eIF-4E) - Products under Development by Therapy Area 8 Eukaryotic Translation Initiation Factor 4E (eIF-4E) - Products under Development by Indication 9 Eukaryotic Translation Initiation Factor 4E (eIF-4E) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Eukaryotic Translation Initiation Factor 4E (eIF-4E) - Products under Development by Companies 12 Eukaryotic Translation Initiation Factor 4E (eIF-4E) - Products under Development by Universities/Institutes 14 Eukaryotic Translation Initiation Factor 4E (eIF-4E) - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 18 Assessment by Molecule Type 19 Eukaryotic Translation Initiation Factor 4E (eIF-4E) - Companies Involved in Therapeutics Development 21 eFFECTOR Therapeutics, Inc. 21 Ionis Pharmaceuticals, Inc. 22 Onconova Therapeutics, Inc. 23 Eukaryotic Translation Initiation Factor 4E (eIF-4E) - Drug Profiles 24 4EGI-1 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 briciclib sodium - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 ISIS-EIF4ERx - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 SBI-756 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Small Molecule to Inhibit eIF4E for Oncology - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Small Molecules to Inhibit Translation Initiation Factor-4E for Autism and Oncology - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Eukaryotic Translation Initiation Factor 4E (eIF-4E) - Dormant Projects 31 Eukaryotic Translation Initiation Factor 4E (eIF-4E) - Discontinued Products 32 Eukaryotic Translation Initiation Factor 4E (eIF-4E) - Featured News & Press Releases 33 Nov 24, 2015: Scientists identify promising new melanoma drug 33 Oct 29, 2015: Onconova Therapeutics to Present New Data on Briciclib at 2015 AACR-NCI-EORTC Meeting 34 Apr 21, 2015: Onconova Therapeutics Highlights Briciclib at the 2015 American Association of Cancer Research (AACR) Annual Meeting 34 Jan 04, 2011: Isis Initiates Phase II Lung Cancer Trial With ISIS-EIF4ERx In Combination With Carboplatin And Paclitaxel 35 Feb 01, 2006: Lilly Initiates Clinical Trials On Second Cancer Drug Discovered In Isis Collaboration 36 Jun 24, 2002: Expansion Of Antisense Agreement Between Isis And Eli Lilly 36 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 37 Disclaimer 38
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Assessment by Monotherapy/Combination Products, H1 2016 16 Number of Products by Stage and Mechanism of Action, H1 2016 17 Number of Products by Stage and Route of Administration, H1 2016 18 Number of Products by Stage and Molecule Type, H1 2016 20 Pipeline by eFFECTOR Therapeutics, Inc., H1 2016 21 Pipeline by Ionis Pharmaceuticals, Inc., H1 2016 22 Pipeline by Onconova Therapeutics, Inc., H1 2016 23 Dormant Projects, H1 2016 31 Discontinued Products, H1 2016 32


List of Figures
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Top 10 Indication, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 11 Assessment by Monotherapy/Combination Products, H1 2016 16 Number of Products by Stage and Mechanism of Actions, H1 2016 17 Number of Products by Stage and Routes of Administration, H1 2016 18 Number of Products by Molecule Types, H1 2016 19 Number of Products by Stage and Molecule Type, H1 2016 19

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global automotive coatings market size is likely to be valued at USD 27.7 billion by 2022; as per a new research report by Radiant Insights, Inc. Vehicle aesthetics, UV radiation and temperature variation protection and enhance durability are certain

Read More...

Global aerospace plastics market size is likely to be valued at USD 13.48 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing application scope of lightweight materials in aerospace industry is likely to drive market growt

Read More...

Global coated fabrics market size forecast is estimated at USD 22.57 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing production of seat covers & airbags for automobile applications is likely to favor market growth.

Read More...

Global advanced energy storage systems market size is anticipated to be valued at USD 24.8 billion by 2022, as per a new research report by Radiant Insights, Inc. Increasing energy consumption coupled with strong energy demand for industrial, commerc

Read More...

Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expected

Read More...
Choose License Type
Single User - US $3500
Multi User - US $7000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify